← IDEAYA Biosciences, Inc. (IDYA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IDEAYA Biosciences, Inc. (IDYA)
Pharmaceutical Preparations · market cap $3.7B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-23
Conference
Pipeline
5
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
IDEAYA Biosciences (IDYA) is a ~$3.2B market cap oncology-focused biotech with 131 employees and a pipeline centered on uveal melanoma and select solid tumors. The company carries $157.5M in cash against a burn rate implying roughly 6 months of runway, creating near-term financing urgency. Multiple Phase 2/3 readouts for its lead uveal melanoma program (Crizotinib, IDE196, Darovasertib) are expected between late 2026 and mid-2027.
The catalyst path
- 2026-10-23Conferenceimp 4/10
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-31NDA Filingimp 8/10
- 2026-12-31 (est.)Phase 2 · IDE196imp 7/10
- 2027-01-15 (est.)Phase 3 · IDE196imp 9/10
- 2027-01-29 (est.)Phase 2 · Crizotinibimp 7/10
- 2027-01-29 (est.)Phase 3 · Crizotinibimp 9/10
- 2027-04-30 (est.)Phase 2 · Darovasertibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IDE574 | Phase 2 | ER+, HER 2- Breast Cancer |
| Crizotinib | Phase 3 | Metastatic Uveal Melanoma |
| Darovasertib | Phase 3 | Uveal Melanoma |
| IDE196 | Phase 3 | Metastatic Uveal Melanoma |
| IDE849 | Phase 2 | Small-cell Lung Cancer |
Price & technical context
3-month
+0.4%
6-month
+16.4%
12-month
+39.0%
52-wk range
$26.24–$42.48
vs 50-day MA
-0.4%
vs 200-day MA
+11.0%
Realized vol
45.3%
Max drawdown
-61.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IDYA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.